drugset / Trial / NCT00451880
Study of XL281 in Adults With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
Timeline
- Start
- 2007-02
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famotidine | Other / unclassified | 20 mg | — |
| Subject | Famotidine | Other / unclassified | 40 mg | — |
| Subject | XL281 | Small molecule | 5 mg | Oral |
| Subject | XL281 | Small molecule | 25 mg | Oral |
| Subject | XL281 | Small molecule | 100 mg | Oral |